GI Bleeding Flashcards
Approximately 50% of admissions
for GI bleeding are for
upper GI (UGI) bleeding (from the esophagus, stomach, and duodenum), 40% are for lower GI (LGI) bleeding (from the colon and anorectum), and 10% are for obscure bleeding (from the small intestine)
Severe GI bleeding
hematemesis, melena, hematochezia, or positive nasogastric lavage) accompanied by shock or orthostatic hypotension,
a decrease in the hematocrit value by at least 6% (or a decrease in the hemoglobin level of at least 2 g/dL), or transfusion of at least 2 units of packed red blood cells.
Hematemesis is defined as vomiting of blood, which is indicative of bleeding from the esophagus, stomach, or duodenum.
Hematemesis includes vomiting
of bright red blood, which suggests recent or ongoing bleeding, and dark material (coffee-ground emesis), which suggests
bleeding that stopped some time ago
Melena
can signify bleeding that originates from a UGI, small bowel,
or proximal colonic source and generally occurs when
50 to 100 mL or more of blood is delivered into the GI tract (usually the upper tract), with passage of characteristic stool occurring several hours after the bleeding event
refers to
bright red blood per rectum and suggests active UGI or small bowel bleeding or distal colonic or anorectal bleeding
Hematochezia
refers to subacute bleeding that is not clinically
visible.
Occult
GI bleeding
is bleeding from a site that is not
apparent after routine endoscopic evaluation with esophagogastroduodenoscopy (upper endoscopy) and colonoscopy,
and possibly small bowel radiography
Obscure GI bleeding
for the vascular space to equilibrate with extravascular fluid, and hemodilution results from intravenous administration of saline.
it takes over 24 to 72 hours
A
mean corpuscular volume (MCV) lower than 80 fL suggests
chronic GI blood loss and iron deficiency, which can be confirmed by the finding of low blood iron, high total iron-binding capacity (TIBC), and low ferritin levels
suggests chronic liver disease
or folate or vitamin B12 deficiency.
A high MCV (>100 fL)
An elevated white blood
cell count may occur in more than half of patients with UGI
bleeding and has been associated with greater severity of
bleeding.6
A low platelet count can contribute to the severity
of bleeding and suggests chronic liver disease or a hematologic disorder
Maroon-colored stool can be seen with an
actively bleeding UGI source or a small intestinal or proximal
colonic source
Patients should be transfused with
packed red blood cells, platelets, and fresh frozen plasma as
necessary to keep the hemoglobin level greater than
7 gm/dL,
platelet count higher than 50,000/mm3
, and prothrombin time
less than 15 seconds, respectively.
7 g/dL or when the hemoglobin level was less than
9 g/dL.14 The former (“restrictive”) transfusion strategy was
associated with a higher survival rate and lower rebleeding
rate in patients with bleeding due to
peptic ulcer or ChildPugh class A or B cirrhosis but the opposite results in those with Child-Pugh class C cirrhosis
infusion of a PPI in a high dose
before endoscopy accelerates the resolution of endoscopic
stigmata of bleeding in ulcers (see later) and reduces the need
for endoscopic therapy but
does not result in improvement in
the transfusion requirement, rebleeding rate, need for surgery,
or death rate
Patients with a strong suspicion of portal
hypertension and variceal bleeding should be started empirically on intravenous octreotide (bolus followed by infusion which can reduce the risk of
rebleeding to a rate similar to that following endoscopic therapy
Patients who are hemodynamically stable without evidence of ongoing
bleeding can undergo urgent endoscopy (within 12 hours),
often in the GI endoscopy unit rather than the ICU.
sary
Middleof-the-night endoscopy should be avoided, except for the most
severely bleeding or high-risk patients, because well-trained
endoscopy nurses, optimal endoscopic equipment, and surgical backup may not be available at night. In the rare patient
with massive bleeding and refractory hypotension, endoscopy
can be performed in the operating room, with the immediate
availability of surgical management
severe UGI bleeding, gastric lavage with a large (34 French) orogastric tube should be performed to evacuate blood and clots from the stomach to prevent aspiration and allow adequate endoscopic visualization
Using iced saline lavage to prevent
or decrease UGI bleeding is of no value and may impair coagulation and cause hypothermia.
Gastric lavage with lukewarm
tap water is as safe as lavage with sterile saline and much less
expensive.
placed on the tip of the endoscope can help to visualize bleeding sites behind mucosal
folds, deploy endoscopic clips by modifying the angle of
endoscopic approach, avoid mucosal “white-out” at corners,
and remove blood clots
A clear plastic cap
Patients should receive 6 to 8 L of polyethylene glycol purge
orally or via a nasogastric tube over
4 to 6 hours until the rectal
effluent is clear of stool, blood, and clots
Metoclopramide, 10 mg,
may be given intravenously before the purge and repeated every 4 to 6 hours to facilitate gastric emptying and reduce nausea
. In patients with severe or ongoing active hematochezia, urgent colonoscopy should be performed within 12 hours,
but only after thorough cleansing of the colon.
Patients with
mild or moderate self-limited hematochezia should undergo
colonoscopy within 24 hours of admission after a colonic
purge
Capsule endoscopy has the advantage of directly
visualizing the small intestine to identify potential sources or
active bleeding. Disadvantages are that the procedure
takes 8
hours to complete
Injection therapy is most commonly performed with a
sclerotherapy needle and submucosal injection of epinephrine, diluted to a concentration of
1 : 10,000 or 1 :20,000, into or
around the bleeding site or stigma of hemorrhage
Injection therapy can also be performed
with a sclerosant, such as ethanolamine or alcohol, but
these agents are associated with increased tissue damage and
other risks.
Angiography generally is diagnostic of
extravasation into the intestinal lumen only when the arterial bleeding rate is at least
0.5 mL/min.
The sensitivity of mesenteric angiography is 30% to 50% (with higher sensitivity rates for active GI bleeding than for recurrent acute or chronic occult bleeding), and the specificity is 100%
Radionuclide imaging has been reported to detect
bleeding at a rate of
0.04 mL/min
bleeding (bleeding scans) are technetium
sulfur colloid and technetium pertechnetate–labeled autologous red blood cells
The rate of true-positive scans is higher for active bleeding with hemodynamic instability than for less severe bleeding.
The most common reason for a false-positive result is rapid transit of luminal blood, such that labeled blood is detected in the colon even though it originated from a more proximal site
in the GI tract.
Technetium pertechnetate scintigraphy can identify ectopic
gastric mucosa in a
Meckel’s diverticulum. This diagnosis
should be considered in a pediatric or young adult patient
with unexplained GI bleeding
Of the potential causes of severe UGI bleeding, peptic ulcer is
the most common, accounting for approximately
40%
mortality rate of 5% to 10%
for severe UGI bleeding has not changed since
riceal bleeding.
Bleeding is self-limited in
80% of patients with UGI hemorrhage, even without specific therapy.
Of the remaining 20% who continue to bleed or rebleed, the mortality rate is 30% to 40%.
peptic ulcer, most commonly gastric or duodenal
ulcer, accounted for
50% of UGI bleeds
The
mortality rate associated with peptic ulcer bleeding is 5% to 10%
Factors Predictive of a Poor Prognosis afterHemorrhage from Peptic Ulcer
Age > 60 years
Bleeding onset in hospital
Comorbid medical illness
Shock or orthostatic hypotension
Fresh blood in nasogastric tube
Coagulopathy
Multiple transfusions required
Higher lesser curve gastric ulcer (adjacent to left gastric artery)
Posterior duodenal bulb ulcer (adjacent to gastroduodenal
artery)
Endoscopic finding of arterial bleeding or visible vessel
The prevalence of Hp infection is over
80% of the population in many developing countries and 20% to 50% in industrialized countries.
Hp gastritis most commonly involves the
antrum and predisposes patients to duodenal ulcers,
whereas
gastric body–predominant gastritis is associated with gastric
ulcers.
Gastric ulcers are about 4 times as
common as duodenal ulcers in patients who take NSAIDs.
Patients at high risk
of rebleeding without treatment are those with a
active arterial bleeding (90%), an NBVV (50%), or an adherent clot (33%)
endoscopic hemostasis alone decreases
the rebleeding rate to approximately 15% to 30% The adjunctive intravenous administration of a high-dose PPI
(e.g., pantoprazole, 80-mg bolus and 8 mg/hr for 72 hours) decreases this rate even further
An endoscopically identified NBVV that has a translucent (pearl or whitish) color has a higher risk of rebleeding than a
darkly colored pigmented protuberance (clot), because the translucent stigma likely represents the arterial wall
Patients with major stigmata of ulcer hemorrhage (spurting, NBVV, or adherent clot) benefit most from
endoscopic hemostasis, whereas those with a flat spot or clean
ulcer base do not.
Patients with oozing bleeding and no other
stigma (e.g., a clot or NBVV) may benefit from endoscopic
hemostasis but not from a high-dose PPI infusion
The risk of rebleeding from a peptic ulcer decreases significantly
72 hours after the initial episode of bleeding.
untreated NBVVs have found that these lesions resolve over 4 days and adherent
clots tend to resolve over 2 days.
The most commonly used treatment for ulcer bleeding
worldwide is
epinephrine injection therapy; it is widely available, easy to perform, safe, and inexpensive. Therapy with epinephrine alone seems to be more effective when used inhigh doses (13 to 20 mL) than in low doses (5 to 10 mL)
application of hemoclips was
shown to be superior to that for
epinephrine injection alone
but comparable to that for thermocoagulation
is generally defined as a blood clot over an ulcer that is resistant to several minutes of vigorous target jet water irrigation
An adherent clot
Randomized controlled studies have shown that
endoscopic treatment of an adherent clot can decrease the
rebleeding rate to less than 5%
Patients with clean-based ulcers at endoscopy after target irrigation have a rebleeding rate of
less than 5%
inject 0.5- to 1-mL aliquots of epinephrine (1 :20,000) via a sclerotherapy needle
into 4 quadrants of the ulcer within 1 to 2 mm of the bleeding site
After epinephrine injection, the thermal probe is placed directly on the bleeding site to tamponade the site and stop the bleeding, and coagulation is applied with long (10- second
Intravenous H2 receptor antagonists can raise the intragastric pH acutely, but tolerance to these agents develops rapidly
and the pH usually returns to 3 to 5 within 24 hours.
Several
studies have shown that in normal subjects, intravenous
administration of a PPI can consistently keep gastric pH
higher than 4 (and often 6) over a 72-hour infusion.
intravenous H2 receptor antagonists for the prevention of
recurrent ulcer bleeding have shown no definite benefit
no difference between high-dose intravenous continuous infusion of a PPI (80 mg bolus followed by 8 mg/hr for 3
days) and
non–high-dose intermittent or oral administration
(for 3 days)
Whether oral administration is as effective as
intravenous administration of a PPI is unclear, although
studies have shown that high-dose oral administration (e.g., omeprazole, 40 mg twice daily) reduces rebleeding to rates that would be expected from endoscopic hemostasis
In fact, the increase in intragastric pH with high-dose oral PPI administration is almost identical (although delayed by 1 hour) to that with intravenous PPI administration.1
decreases the risk of rebleeding from peptic ulcers when compared with placebo or an H2 receptor blocker.
octreotide
The proposed
mechanisms of action include a reduction in splanchnic and
gastroduodenal mucosal blood flow, a decrease in GI motility,
inhibition of gastric acid secretion, inhibition of pepsin secretion, and gastric mucosal cytoprotective effects
Somatostatin or octreotide can be considered in
patients with severe ongoing bleeding who are not responsive
to endoscopic therapy, an intravenous PPI, or both, and are
not surgical candidates, although their effectiveness in these
patients is uncertain
routine second-look
endoscopy is not recommended for most patients with peptic
ulcer bleeding,
except in those in whom the initial endoscopic examination was suboptimal because excessive blood
obscured the view, technical problems with hemostasis
occurred, clinically significant bleeding recurred, or less effective endoscopic techniques such as epinephrine injection alone
The risk of rebleeding from peptic ulcers that started bleeding
in the outpatient setting and required endoscopic hemostasis
is greatest in the first
72 hours after diagnosis and treatment.
Factors that predicted failure of endoscopic retreatment included an
ulcer size of at least 2 cm and hypotension
on initial presentation
recurrent bleeding despite 2 sessions of endoscopic hemostasis should be considered for
angiographic
embolization or surgical therapy
For patients with severe atherosclerotic cardiovascular
disease who require aspirin, however, a dose of 81 mg/day
should be started within
7 days.